BRCA1/2 gene mutations are inherited from a parent or acquired in the cells of a tumour. With advances in personalized cancer treatment, knowledge BRCA1/2 mutations (inherited or acquired) can direct cancer treatment, particularly ovarian cancer. This has increased requests for multiple types genetic testing, requiring changes to current genetic testing models. Led by the Society of Gynecologic Oncology Canada, a national multi-disciplinary Community of Practice was assembled and described the genetic testing landscape in BRCA1/2-related ovarian cancer.  It also proposes a national strategy to increase genetic testing rates and improve outcomes for BRCA1/2-related ovarian cancer patients and their families. (By Dr Raymond H Kim, https://jmg.bmj.com/content/early/2018/07/24/jmedgenet-2018-105472 )